Supriya Lifescience Limited's 18th AGM: All resolutions passed, including final dividend declaration
Supriya Lifescience Limited's 18th AGM on September 24, 2026, saw all resolutions passed. Key approvals included the FY26 financial statements and a final dividend of ₹1.00 per share. Directors Dr. Saloni Wagh and Ms. Shivani Wagh were re-appointed, and Cost Auditors' remuneration for FY27 was ratified.
The AGM proceedings and the passing of resolutions, especially the dividend declaration, are important for shareholders and reflect the company's operational and financial health, thus having a medium impact.
The announcement reports the successful passing of all resolutions at the AGM, including the declaration of a final dividend and re-appointment of directors, indicating positive corporate governance and shareholder confidence.
Supriya Lifescience Limited held its 18th Annual General Meeting (AGM) on September 24, 2026, commencing at 3:00 PM IST and concluding at 3:50 PM IST, through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). All resolutions presented at the AGM were passed with the requisite majority.
The businesses transacted included the approval and adoption of the Audited Financial Statements for the financial year ended March 31, 2026, along with the Board of Directors' and Auditors' reports. The company also declared a Final Dividend of ₹1.00 per equity share (50%) for the Financial Year ended March 31, 2026. Additionally, directors Dr. Saloni Wagh and Ms. Shivani Wagh, who retired by rotation, were re-appointed. The remuneration of the Cost Auditors for FY 2026-27 was also ratified.
The voting results, along with the consolidated report of the scrutinizer, have been submitted to the stock exchanges and will be uploaded on the company's website and the NSDL website. The company had facilitated remote e-voting from September 21, 2026, to September 23, 2026, and also provided an option for e-voting during the AGM.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.